FDA Rejects Coherus’ Neulasta Biosimilar, Calls for New Analyses By Sam | July 6, 2017 The FDA rejected Coherus Bioscience’s proposed biosimilar for Amgen’s Neulasta, Coherus announced. Source: Generic Line Posted in Generic Line